Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03999710 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT03999710 · ClinicalTrials.gov record · last posted 2026-08-05

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

Name: Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer — clinical trial record (NCT03999710)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorMemorial Sloan Kettering Cancer Center

Started2019-07-19

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this study is to see if Durvalumab and radiation therapy can delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy.

Protocol amendment history 2 changes detected by DataLookout

2026-08-06

Primary completion pushed: 2026-07 → 2027-07

2026-08-06

Completion pushed: 2026-07 → 2027-07

Trial Details

NCT Number	NCT03999710
Lead Sponsor	Memorial Sloan Kettering Cancer Center
Conditions	Non Small Cell Lung Cancer, Lung Cancer, Nsclc, NSCLC Stage II, NSCLC, Stage III
Enrollment	61 participants
Start Date	2019-07-19
Primary Completion	2027-07 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2026-08-05